• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Pressemeddelelse

The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.

Attana

The Swedish Knowledge-Foundation has granted SEK 12 million to the project "Advanced materials for individualized medicine and diagnostics (https://www.kks.se/article/35-miljoner-till-forskning-i-samproduktion-med-naringslivet/)". The project is coordinated by Prof. Ian Nicholls at Linnaeus University (https://lnu.se/en/research/research-projects/project-advanced-materials-for-personal-medicine-and-diagnostics/) in collaboration with Attana AB, AroCell AB, Capitainer AB, Luma Metall AB and Region Kalmar.

The aim of the project is to provide precise information about the medical conditions of individuals and groups to optimize vaccination and medical treatment. It enables individuals, patients, care providers and decision makers, as well as researchers to optimize their decisions. The project includes the entire chain from sampling, via analysis to reporting. The project's participants gather expertise from the commercial and public sectors as well as researchers and developers.

The project consists of four sub-projects:

1. Biomarkers: Cancer biomarker detection - small cell lung cancer (Project manager: Ian Nicholls).

2. Viruses: Virus-related diseases: e.g. COVID-19 and hepatitis (Project manager: Per Nilsson).

3. Bacteria: Enhanced bacterial infection diagnosis - Lyme disease & E.coli related urinary tract infections (Project manager: Sofia Somajo).

4. Tissue samples: Biosensor-based histology - glaucoma & macular degeneration (Project manager: Camilla Mohlin).

Sub-project 1-3 builds directly on Attana's immunity profile concept and sampling with Capitainer's qDBS concept. Subproject 4 is based on Attana's tissue-based biosensors.

Shortly we will publish PMs regarding each specific sub-project and its importance for Attana.

Attana's CEO Teodor Aastrup comments:

"The project strengthens our capabilities in immunity profiles and ensures the necessary expertise and funding for the further development of immunity profiles. Thereby we can allocate the necessary resources to this project and at the same time focus other resources on our regular commercial activities."